Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Brokerages

Fate Therapeutics, Inc. (NASDAQ:FATE) has been assigned an average recommendation of “Hold” from the eight ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $4.10.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fate Therapeutics in a report on Thursday, January 22nd.

Fate Therapeutics Stock Down 4.9%

Shares of NASDAQ:FATE opened at $1.17 on Monday. Fate Therapeutics has a 52-week low of $0.66 and a 52-week high of $1.94. The stock has a market cap of $136.02 million, a price-to-earnings ratio of -1.02 and a beta of 2.19. The business has a 50-day moving average price of $1.25 and a 200-day moving average price of $1.18.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.27) EPS for the quarter, meeting analysts’ consensus estimates of ($0.27). Fate Therapeutics had a negative return on equity of 55.02% and a negative net margin of 2,051.08%.The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $1.20 million. As a group, equities analysts anticipate that Fate Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Fate Therapeutics

A number of hedge funds have recently modified their holdings of FATE. Corient Private Wealth LLC acquired a new position in shares of Fate Therapeutics in the fourth quarter worth about $29,000. Bridgeway Capital Management LLC purchased a new stake in shares of Fate Therapeutics during the 2nd quarter worth about $28,000. Commonwealth Equity Services LLC acquired a new stake in shares of Fate Therapeutics during the 4th quarter valued at about $26,000. Monaco Asset Management SAM grew its position in shares of Fate Therapeutics by 7.8% during the 4th quarter. Monaco Asset Management SAM now owns 830,000 shares of the biopharmaceutical company’s stock valued at $816,000 after acquiring an additional 60,000 shares during the period. Finally, Privium Fund Management B.V. increased its stake in shares of Fate Therapeutics by 10.8% in the 4th quarter. Privium Fund Management B.V. now owns 369,100 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 35,881 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate’s research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate’s pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.